Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 413-910-1 | CAS number: 1467668-33-2 LUPEROX 610-E-35; LUPEROX 610-E-50; LUPEROX 610-EN-50; LUPEROX 610-M-50; LUPERSOL 610; LUPERSOL 610-M-50
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The LD0 in rats exposed to 3-hydroxy-1,1-dimethylbutylperoxy-neodecanoate are more than 2000 mg/kg after oral or dermal exposure.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMAL
- Source: Iffa Credo (69210 L'Arbresle, France)
- Age: 6 weeks
- Weight at study initiation: 174 ± 9 g (males) and 150 ± 3 g (females)
- Upon their arrival at the laboratory, the animals were acclimatized to the experimental environment for at least 5 days during which they were observed daily.
- Animals were individually identified by earmarks or earnotches
- Diet: ad libitum
- Food: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature : 22 ± 3°C
- Humidity : 50 ± 20% relative humidity
- Light/dark cycle: 12 hours of light/12 hours of dark
- The air was non-recycled and filtered by absolute filters.
- The animals were housed in groups of 4 to 7 animals of the same sex during the acclimatization period and groups of 5 animals of the same sex during the study.
- The day before treatment, the animals were fasted for a period of approximately 18 hours before administration of the test substance. They were then given food 4 hours after treatment. - Route of administration:
- oral: gavage
- Vehicle:
- other: none
- Details on oral exposure:
- - Volume administered: taking into consideration the specific gravity of the test substance (0.96)
- Post dose observation period: 14 days - Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5 males + 5 females
- Control animals:
- no
- Details on study design:
- - Clinical signs: examined at least once a day
- Mortality: recorded at least twice a day
- Body weight: measured just before administration then on days 5, 8 and 15.
- Necropsy: . macroscopic examination of the main organs: digestive tract, heart, kidneys, liver, lungs, pancreas, spleen and any other organs with obvious abnormalities.
- Microscopic examination: no - Statistics:
- none
- Sex:
- male/female
- Dose descriptor:
- LD0
- Effect level:
- >= 2 000 mg/kg bw
- Mortality:
- No deaths occurred during the observation period.
- Clinical signs:
- other: No clinical signs were observed during the study.
- Other findings:
- NECROPSY FINDINGS: No apparent abnormalities.
Due to the absence of macroscopic lesions, no organ samples were taken and no histological examination was performed. - Interpretation of results:
- study cannot be used for classification
- Remarks:
- Migrated information
- Conclusions:
- Under the experimental conditions, the LD0 of the test substance administered by oral route in rats was higher than 2000 mg/kg. No signs of toxicity were observed at this dose level.
- Executive summary:
The test substance was administered by oral route to a group of 10 fasted Sprague-Dawley rats (5 males and 5 females) in an acute toxicity test by oral route (OECD 401, GLP).
The test substance was administered in its original form at a dose level of 2000 mg/kg at a volume taking into consideration that the specific gravity of the test substance was .96.
The mortality, general behaviour and body weight gain of the animals were observed for a period of 14 days after the single administration of the test substance. A necropsy was performed on each animal sacrificed at the end of the study.
The general behaviour and body weight gain of the animals were not influenced by the treatment. No deaths occurred at the dose level of 2000 mg/kg. The macroscopic examination revealed no abnormalities in the animals sacrificed at the end of the study.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMAL
- Source: Iffa Credo (69210 L'Arbresle, France)
- Age: 8 weeks
- Weight at study initiation: 271 ± 7 g (males) and 230 ± 4 g (females)
- Upon their arrival at C.I.T., the animals were acclimatized to the experimental environment for at least 5 days during which they were observed daily.
On the first day of treatment, the adult animals were approximately 8 weeks old, and had a mean weight of 271 ± 7 g for the males and 230 ± 4 g for the females.
- They were individually identified by earmarks or earnotches.
ENVIRONMENTAL CONDITIONS
- Temperature : 22 ± 3°C
- Humidity : 50 ± 20% relative humidity
- Light/dark cycle: 12 hours of light/12 hours of dark
- The air was non-recycled and filtered by absolute filters.
- Food and water: ad libidum - Type of coverage:
- semiocclusive
- Vehicle:
- other: none
- Details on dermal exposure:
- - Area covered: approximately 10%
- Exposure: semi-occlusive
- Concentration in vehicle: undiluted
- Total volume applied: according to the body weight determined on the day of treatment and test substance specific gravity (0.96)
- Removal of test substance: no
- Exposure duration: 24 hours
- Post-dose observation period: 14 days
- The day before treatment, the dorsal area of each animal was clipped with an electric clipper on an area of 6 x 8 cm. Only animals with healthy intact skin were used for the study.
- A hydrophilic gauze patch was applied to the skin
- The test substance and the gauze patch were held in contact with the skin for 24 hours by means of an adhesive hypoallergic aerated semi-occlusive dressing attached to a restraining bandage. This dressing prevented the ingestion of the test substance by the animal. No residual test substance was observed at removal of the dressing. - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- - Number of animals: 5 males + 5 females
- Control animals:
- no
- Details on study design:
- - Clinical signs: examined at least once a day
- Mortality: recorded at least twice a day
- Body weight: measured just before administration then on days 5, 8 and 15.
- Necropsy: . macroscopic examination of the main organs: digestive tract, heart, kidneys, liver, lungs, pancreas, spleen and any other organs with obvious abnormalities.
- Microscopic examination: no, due to the absence of macroscopic lesions - Statistics:
- NONE
- Sex:
- male/female
- Dose descriptor:
- LD0
- Effect level:
- >= 2 000 mg/kg bw
- Mortality:
- No deaths occurred during the observation period.
- Clinical signs:
- other: No clinical signs were observed during the study.
- Other findings:
- NECROPSY FINDINGS: No apparent abnormalities.
- Interpretation of results:
- study cannot be used for classification
- Remarks:
- Migrated information
- Conclusions:
- The LD0 of the test substance administered by dermal route in rats was higher than 2000 mg/kg. No signs of toxicity were observed at this dose level.
- Executive summary:
In an acute toxicity test by dermal route (OECD 402, GLP), the test substance was applied in its original form directly to the skin of 10 Sprague-Dawley rats (5 males and 5 females) at a dose level of 2000 mg/kg, taking into consideration that the specific gravity (SG) of the test substance was 0.96. After 24 hours under a semi-occlusive dressing, no residual test substance was observed.
The mortality, general behaviour and body weight gain of the animals were observed for a period of 14 days after the single application of the test substance. A necropsy was performed on each animal sacrificed at the end of the study.
The general behaviour and body weight gain of the animals were not influenced by the treatment. No deaths occurred at the dose level of 2000 mg/kg.
The macroscopic examination revealed no abnormalities in the animals sacrificed at the end of the study.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
Two well-conducted studies (OECD guideline 402 and 406, GLP) are available for this endpoint. In the first one (Clouzeau, 1992a), the test substance was administered by oral route to a group of 10 fasted Sprague-Dawley rats (5 males and 5 females). In the second study (Clouzeau, 1992b), the test substance was applied in its original form directly to the skin of 10 Sprague-Dawley rats (5 males and 5 females) at a dose level of 2000 mg/kg. In both studies, after 14 days, a necropsy was performed on each animal sacrificed. The general behaviour and body weight gain of the animals were not influenced by the treatment. No deaths occurred at the dose level of 2000 mg/kg. The macroscopic examinations revealed no abnormalities in the animals sacrificed at the end of the study.In conclusion, the LD0 in rats exposed to 3-hydroxy-1,1-dimethylbutylperoxy-neodecanoate are more than 2000 mg/kg after oral or dermal exposure.
Justification for selection of acute toxicity – oral endpoint
Key study
Justification for selection of acute toxicity – dermal endpoint
Key study
Justification for classification or non-classification
According to EU Regulation (EC) N0. 1272/2008 (CLP), the substance is not classified for acute toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.